LakeShore Biopharma 6-K: Going-private merger pact with Oceanpine

LakeShore Biopharma (LSB) filed a Form 6‑K announcing it has entered into a definitive agreement for a going‑private transaction.

Rhea-AI Filing Summary

LakeShore Biopharma (LSB) filed a Form 6‑K announcing it has entered into a definitive agreement for a going‑private transaction. The filing furnishes two exhibits: a press release and an Agreement and Plan of Merger dated November 4, 2025.

The merger agreement is among LakeShore Biopharma Co., Ltd, Oceanpine Skyline Inc., and Oceanpine Merger Sub Inc. The 6‑K provides notice of the agreement and includes the full documents as exhibits.

Insights

M&A analyst

Definitive going‑private agreement disclosed; terms not included here.

LakeShore Biopharma furnished a Form 6‑K with a definitive Agreement and Plan of Merger dated November 4, 2025, naming Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. as counterparties. A definitive agreement typically signals the parties have agreed on key deal terms and structure.

The exhibits listed are a press release and the merger agreement, indicating formal progress toward a going‑private transaction. The excerpt does not state consideration, closing conditions, or timeline, so financial impact cannot be assessed from this text alone.

Subsequent filings may provide transaction consideration, closing conditions, and expected timing, which would clarify valuation and next steps.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LakeShore Biopharma (LSB) disclose in this Form 6-K?

It furnished a press release and an Agreement and Plan of Merger for a going‑private transaction.

Who are the counterparties to LakeShore Biopharma’s merger agreement?

Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc.

What is the date of the Agreement and Plan of Merger for LSB?

November 4, 2025.

What exhibits are included with LakeShore Biopharma’s 6-K filing?

Exhibit 99.1: Press Release; Exhibit 99.2: Agreement and Plan of Merger.

What transaction type is LakeShore Biopharma pursuing?

A going‑private transaction under a definitive merger agreement.

Which form did LakeShore Biopharma use for this disclosure?

Form 6‑K as a report of a foreign private issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/04/2025 - 07:13 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission file number: 001-41598

LAKESHORE BIOPHARMA CO., LTD 

(Exact name of registrant as specified in its charter)

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  

Form 20-F  ☒          Form 40-F  ☐

EXHIBITS

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
99.2		Agreement and Plan of Merger, dated November 4, 2025, by and among LakeShore Biopharma Co., Ltd, Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc.

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

Date: November 4, 2025

2